Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
A shareholder of EMN has filed a Rule 144 notice to sell 6,016 common shares through Fidelity Brokerage Services LLC on or about 02/04/2026, to be sold on the NYSE with an aggregate market value of $475,011.96.
The shares come from restricted stock that vested as compensation on 02/19/2021, 10/15/2022, and 02/15/2023, in amounts of 2,249, 1,040, and 2,727 shares. Shares outstanding were 114,069,800 at the time of the notice; this is a baseline figure, not the amount being sold.
Eastman Chemical Company filed a current report to furnish its financial results for the fourth quarter of 2025. The company states that it publicly released these results on January 29, 2026, and has attached the full earnings press release as an exhibit.
The earnings release is provided as Exhibit 99.01 and is incorporated by reference, but is designated as “furnished” rather than “filed” under securities law, which affects how it is treated for certain legal liabilities and future regulatory filings.
Eastman Chemical Company reported an equity award to executive officer Stephen G. Crawford, EVP, Technology Projects. On 01/02/2026, he received 34,193 restricted stock units (RSUs), each representing a contingent right to receive one share of Eastman Chemical common stock. These RSUs were reported as derivative securities beneficially owned directly.
The RSUs carry a conversion price of $0 and are scheduled to vest and pay out in unrestricted shares of common stock on February 2, 2027, subject to Mr. Crawford’s continued employment. After this grant, he beneficially owns 34,193 derivative securities in the form of RSUs tied to Eastman Chemical common stock.
BlackRock, Inc. has filed an amended Schedule 13G reporting a significant passive ownership position in Eastman Chemical Co common stock. As of the event date of 11/30/2025, BlackRock reports beneficial ownership of 13,598,433 shares, representing 11.9% of Eastman Chemical’s outstanding common stock. BlackRock has sole voting power over 13,254,753 of these shares and sole dispositive power over all 13,598,433 shares, with no shared voting or dispositive power.
The filing is made on a passive basis, with BlackRock certifying the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Eastman Chemical. The filing notes that one underlying holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Eastman Chemical’s outstanding common stock.
Eastman Chemical (EMN) executive Stephen G. Crawford, EVP, Technology Projects, filed an initial statement of beneficial ownership. He reports 60,301 shares of common stock held directly, plus indirect holdings through retirement plans and spouse accounts.
He also lists employee stock options covering multiple grants, including 24,527 shares at $86.15 expiring 02/26/2034 and 25,883 shares at $83.84 expiring 02/23/2033. Vesting schedules note one‑third becoming exercisable on specified dates in 2025–2027 for recent grants.
Eastman Chemical (EMN) reported weaker Q3 2025 results. Sales were $2,202 million versus $2,464 million a year ago, and earnings before income taxes were $134 million versus $280 million. Net earnings were $47 million, with diluted EPS of $0.40 compared to $1.53.
Segment performance softened: total segment Adjusted EBIT was $249 million versus $407 million, with declines in Advanced Materials ($53 million vs $122 million), Chemical Intermediates ($1 million vs $43 million), and Fibers ($67 million vs $112 million). Additives & Functional Products was $128 million versus $130 million. The effective tax rate rose to 65%, reflecting impacts from the One Big Beautiful Bill Act and uncertain tax positions.
Year-to-date cash from operations was $468 million, capital expenditures $434 million, and net interest expense $156 million. Total borrowings were $5,075 million, including $290 million of commercial paper. Environmental reserves increased to $322 million. The company received $14 million of DOE reimbursements tied to a terminated grant related to the Longview, Texas recycling project.
Eastman Chemical Company reported that on November 3, 2025 it publicly released its financial results for third quarter 2025. The company made these results available through a press release that is furnished as Exhibit 99.01 to its current report. The information in the press release is treated as furnished, not filed, under the Securities Exchange Act of 1934 and is only incorporated into other securities filings if specifically referenced. The report is signed on behalf of Eastman Chemical Company by Michelle R. Stewart, Vice President, Chief Accounting Officer and Corporate Controller.
Damon J. Audia, a director of Eastman Chemical Co. (EMN), reported crediting of 1,360 phantom stock units on 10/07/2025 under the Directors' Deferred Compensation Plan. The report shows two entries: 873 units credited at a market-linked value of $62.35 each and 487 units credited with a $0 price (automatic deferral), totaling 1,360 units beneficially owned following the transactions. These phantom units mirror the market value of one share each but are payable only in cash after the director's service ends, and thus do not represent actual shares with voting rights.
The Form 4 was filed as a single reporting person filing and signed by power of attorney on 10/09/2025. The entries reflect voluntary and automatic deferrals of director retainer fees into the director's deferred stock account rather than open-market purchases or option exercises.
Eastman Chemical (EMN) director Renee J. Hornbaker reported an automatic deferral under the Directors' Deferred Compensation Plan. On 10/07/2025, she was credited with 487 phantom stock units (value equal to one share of common stock), at a price of $0, reflecting a portion of her annual retainer fees. Phantom units are payable only in cash after service as a director ends.
Following the transaction, she beneficially owned 49,781 derivative securities. This total includes 1,151 units credited since April 7, 2025 as hypothetical reinvestment of dividend equivalents.
Eastman Chemical (EMN) director Linnie M. Haynesworth reported acquiring 487 Phantom Stock Units on 10/07/2025 at $0, reflecting an automatic deferral of a portion of her annual director retainer into the Directors' Deferred Compensation Plan. After the transaction, she beneficially owns 3,559 phantom units. Each unit has a value equal to one share of common stock and is payable only in cash after her service as a director ends. The total includes 42 units credited since May 1, 2025 as hypothetical reinvestment of dividend equivalents.